Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.
Robinson JG, Farnier M, Kastelein JJP, Roth EM, Taskinen MR, Colhoun HM, Brunet A, DiCioccio AT, Lecorps G, Pordy R, Baccara-Dinet MT, Cannon CP.
Robinson JG, et al.
J Clin Lipidol. 2019 Nov-Dec;13(6):979-988.e10. doi: 10.1016/j.jacl.2019.10.004. Epub 2019 Oct 14.
J Clin Lipidol. 2019.
PMID: 31708410
Free article.
Clinical Trial.